ATLANTA, Jan. 3 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today that it will present at the 24th Annual JPMorgan Healthcare Conference on Tuesday, January 10, 2006 at 9:30 a.m. PST (12:30 p.m. EST) from the Westin St. Francis Hotel in San Francisco. William D. Johnston, Ph.D., president and chief executive officer of Inhibitex, will provide a company update and discuss its late stage clinical programs for Veronate and Aurexis.
The live audio webcast of the presentation will be available on the “Investors” section of the Company’s website at www.inhibitex.com. The webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. The Company currently has five drug development programs, all of which are based on its proprietary MSCRAMM protein platform technology. The Company’s most advanced product candidates are Veronate, which is currently being evaluated in a pivotal Phase III clinical trial for the prevention of hospital-associated infections in very low birth weight infants, and Aurexis, which is being assessed in various clinical trials as a treatment for infections caused by Staphylococcus aureus. The Company has retained all world-wide rights to Veronate and Aurexis, both of which have been granted Fast Track designation by the FDA. The Company’s preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
CONTACTS: Inhibitex, Inc. Russell H. Plumb Chief Financial Officer (678) 746-1136 rplumb@inhibitex.com Lilian Stern (Investors) Stern Investor Relations, Inc. (212) 362-1200 lilian@sternir.com Kathryn Morris (Media) KMorrisPR (845) 635-9828 kathryn@kmorrispr.com
Inhibitex, Inc.
CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Investors, Lilian Stern ofStern Investor Relations, Inc., +1-212-362-1200, or lilian@sternir.com; orMedia, Kathryn Morris of KMorrisPR, +1-845-635-9828, orkathryn@kmorrispr.com
Web site: http://www.inhibitex.com//
